
Loading, please wait...

Loading, please wait...

Behavioral variant frontotemporal dementia (bvFTD) significantly alters eating habits and swallowing safety. Specifically, dysphagia in bvFTD often goes underdiagnosed due to a lack of standardized assessment protocols. Patients commonly exhibit behavioral changes like hyperphagia, speed eating, and oral packing. These symptoms, although behavioral, pose severe risks including aspiration and pneumonia. Consequently, clinicians must recognize these early signs to prevent life-threatening complications.
A recent systematic review revealed that most studies rely on caregiver questionnaires to identify swallowing issues. However, these reports often conflict with clinical imaging results. For instance, only one study utilized imaging to assess swallowing physiology. Therefore, the lack of objective data makes it difficult to establish evidence-based interventions. Healthcare providers should advocate for more frequent use of Fiberoptic Endoscopic Evaluation of Swallowing (FEES) or videofluoroscopy to ensure diagnostic accuracy.
Effective management requires a multidisciplinary approach involving neurologists, speech-language pathologists, and caregivers. Since patients often lose social graces and eat impulsively, constant supervision during mealtimes is essential. Furthermore, adjusting food textures and bolus sizes can mitigate choking risks. Moreover, future research must focus on developing standardized assessment tools specifically for this unique patient population.
Signs include choking, coughing, and chewing difficulties. Additionally, patients may exhibit hyperphagia, which is characterized by excessive eating or eating too quickly.
Diagnosis currently relies on caregiver reports and screening tools. However, specialists recommend using imaging like FEES for a more definitive physiological assessment.
Untreated dysphagia can lead to aspiration pneumonia, significant malnutrition, and dehydration, which increases the overall mortality rate in dementia patients.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
1. Bailey ES et al. Dysphagia in behavioural variant of frontotemporal dementia- a systematic review. Amyotroph Lateral Scler Frontotemporal Degener. 2026 Apr 16. doi: 10.1080/21678421.2026.2652328. PMID: 41989822.
2. Marin SMC, et al. Swallowing in behavioral variant frontotemporal dementia. SciELO Brazil. 2021.
3. Iacolucci C, et al. Clinical Swallowing Profile of Patients with Frontotemporal Dementia. Neurology. 2019;92(15).

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A systematic review examines the prevalence and diagnostic methods for dysphagia in behavioral variant frontotemporal dementia, highlighting the need for st...
6 months ago

As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today